Drug Profile
UV 4B
Alternative Names: UV 4; UV-4BLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Synergy Pharmaceuticals Inc; University of Oxford
- Developer Emergent BioSolutions; United Therapeutics Corporation
- Class Antivirals; Imino sugars; Small molecules
- Mechanism of Action Alpha-glucosidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue
- Discontinued Influenza virus infections
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Influenza virus infections in USA (PO)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Dengue(In volunteers) in USA (PO, Liquid)